M
Michelle A. Fanale
Researcher at University of Texas MD Anderson Cancer Center
Publications - 302
Citations - 12270
Michelle A. Fanale is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Brentuximab vedotin & Rituximab. The author has an hindex of 46, co-authored 292 publications receiving 10237 citations. Previous affiliations of Michelle A. Fanale include University of Texas at Austin & Memorial Sloan Kettering Cancer Center.
Papers
More filters
Journal ArticleDOI
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro,Ranjana H. Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Timothy M Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle A. Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei R. Shustov +13 more
TL;DR: Targeted therapy with this CD30-directed antibody-drug conjugate brentuximab vedotin may be an effective treatment for relapsed or refractory systemic ALCL and warrants further studies in front-line therapy.
Journal ArticleDOI
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes,Armando Santoro,Margaret A. Shipp,Pier Luigi Zinzani,John M. Timmerman,Stephen M. Ansell,Philippe Armand,Michelle A. Fanale,Voravit Ratanatharathorn,John Kuruvilla,Jonathon B. Cohen,Graham P. Collins,Kerry J. Savage,Marek Trneny,Kazunobu Kato,Benedetto Farsaci,Susan M. Parker,Scott J. Rodig,Margaretha G.M. Roemer,Azra H. Ligon,Andreas Engert +20 more
TL;DR: Nivolumab resulted in frequent responses with an acceptable safety profile in patients with classical Hodgkin's lymphoma who progressed after autologous stem-cell transplantation and brentuximab vedotin, and might be a new treatment option for a patient population with a high unmet need.
Journal ArticleDOI
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert W. Chen,Pier Luigi Zinzani,Michelle A. Fanale,Philippe Armand,Nathalie A. Johnson,Pauline Brice,John Radford,Vincent Ribrag,Daniel Molin,Theodoros P. Vassilakopoulos,Akihiro Tomita,Bastian von Tresckow,Margaret A. Shipp,Yinghua Zhang,Alejandro D. Ricart,Arun Balakumaran,Craig H. Moskowitz +16 more
TL;DR: Pembrolizumab was associated with high response rates and an acceptable safety profile in patients with rrHL, offering a new treatment paradigm for this disease.
Journal ArticleDOI
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial
Jason R. Westin,Fuliang Chu,Min Zhang,Luis Fayad,Larry W. Kwak,Nathan Fowler,Jorge E. Romaguera,Fredrick B. Hagemeister,Michelle A. Fanale,Felipe Samaniego,Lei Feng,Veerabhadran Baladandayuthapani,Zhiqiang Wang,Wencai Ma,Yanli Gao,Michael J. Wallace,Luis M Vence,Laszlo Radvanyi,Tariq Muzzafar,Rinat Rotem-Yehudar,R. Eric Davis,Sattva S. Neelapu +21 more
TL;DR: The combination of pidilizumab and rituximab was well tolerated, with no autoimmune or treatment-related adverse events of grade 3 or 4, and the results suggest that immune checkpoint blockade is worthy of further study in follicular lymphoma.
Journal ArticleDOI
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Philippe Armand,Andreas Engert,Anas Younes,Michelle A. Fanale,Armando Santoro,Pier Luigi Zinzani,John M. Timmerman,Graham P. Collins,Radhakrishnan Ramchandren,Jonathon B. Cohen,Jan Paul De Boer,John Kuruvilla,Kerry J. Savage,Marek Trneny,Margaret A. Shipp,Kazunobu Kato,Anne Sumbul,Benedetto Farsaci,Stephen M. Ansell +18 more
TL;DR: With extended follow-up, responses to nivolumab were frequent and durable and seems to be associated with a favorable safety profile and long-term benefits across a broad spectrum of patients with relapsed/refractory cHL.